Table 1. Comparison of clinicopathological factors based on intratumoural hENT1 and RRM1 expression for all patients (n=127).
| |
|
No. of patients (%) |
|
No. of patients (%) |
|
||
|---|---|---|---|---|---|---|---|
| |
|
High hENT1 |
Low hENT1 |
|
High RRM1 |
Low RRM1 |
|
| Total no. of patients (%) | n=86 (68) | n=41 (32) | P-value | n=67 (53) | n=60 (47) | P-value | |
|
Ages(years) | |||||||
| <70 | 66 (52) | 48 (56) | 18 (44) | 0.209 | 38 (57) | 28 (47) | 0.258 |
| ⩾70 |
61 (48) |
38 (44) |
23 (56) |
|
29 (43) |
32 (53) |
|
|
Gender | |||||||
| Male | 85 (67) | 56 (65) | 29 (71) | 0.529 | 43 (64) | 42 (70) | 0.486 |
| Female |
42 (33) |
30 (35) |
12 (29) |
|
24 (46) |
18 (30) |
|
|
Tumour location | |||||||
| Intrahepatic | 20 (16) | 13 (15) | 7 (17) | 0.251 | 14 (21) | 6 (10) | 0.02 |
| Perihilar | 60 (47) | 37 (43) | 23 (56) | 24 (36) | 36 (60) | ||
| Distal |
47 (37) |
36 (42) |
11 (27) |
|
29 (43) |
18 (30) |
|
|
AGC | |||||||
| Yes | 68 (54) | 45 (52) | 23 (56) | 0.69 | 35 (52) | 33 (55) | 0.755 |
| No |
59 (46) |
41 (48) |
18 (44) |
|
32 (48) |
27 (45) |
|
|
Residual tumour | |||||||
| R0 | 95 (75) | 64 (74) | 31 (76) | 0.885 | 54 (81) | 41 (68) | 0.112 |
| R1 |
32 (25) |
22 (26) |
10 (24) |
|
13 (19) |
19 (32) |
|
|
Pathological differentiation | |||||||
| Well | 55 (43) | 45 (52) | 10 (24) | 0.009 | 33 (49) | 22 (37) | 0.017 |
| Moderately | 49 (39) | 29 (34) | 20 (49) | 28 (42) | 21 (35) | ||
| Poorly |
23 (18) |
12 (14) |
11 (27) |
|
6 (9) |
17 (28) |
|
|
Lymph node metastasis | |||||||
| Present | 65 (51) | 47 (55) | 18 (44) | 0.257 | 36 (54) | 29 (48) | 0.544 |
| Absent |
62 (49) |
39 (45) |
23 (56) |
|
31 (46) |
31 (52) |
|
|
UICC pT factor | |||||||
| T1 | 3 (2) | 2 (2) | 1 (2) | 0.345 | 3 (4) | 0 (0) | 0.126 |
| T2, 2a, 2b | 62 (49) | 38 (44) | 24 (59) | 32 (48) | 30 (50) | ||
| T3 | 59 (46) | 43 (50) | 16 (39) | 29 (43) | 30 (50) | ||
| T4 |
3 (2) |
3 (4) |
0 (0) |
|
3 (4) |
0 (0) |
|
|
UICC stages | |||||||
| II, IIA, IIB | 73 (57) | 49 (57) | 24(58) | 0.544 | 40 (60) | 33 (55) | 0.009 |
| III, IIIA, IIIB | 29 (23) | 18 (21) | 11(27) | 9 (13) | 20 (33) | ||
| IV, IVA, IVB | 25 (20) | 19 (22) | 6(15) | 18 (27) | 7 (12) | ||
Abbreviations: AGC=adjuvant gemcitabine-based chemotherapy; hENT1=human equilibrative nucleoside transporter 1; RRM1=ribonucleotide reductase subunit 1.